World Hemophilia Day 2020: the world gets involved

April 17, 2020 was World Hemophilia Day, and the theme of “Get+involved” was felt around the world despite the challenges of the current COVID19 crisis. From all four corners of the globe, people from the bleeding disorders community took the WFH vision of “Treatment for All” to heart—virtually. On social media, and on—our World Hemophilia Day microsite—people everywhere shared their stories with compelling honesty.

The WFH Facebook pageLinkedIn page and Twitter timeline saw hundreds of updates on the big day. Our World Hemophilia Day microsite—designed to offer visitors information about inherited bleeding disorders, as well as communications material to support them in creating their own activities—was also very popular. Nearly 4,700 people visited the platform, and the pages of the site were viewed over 11,000 times. Over 300 stories were posted on the platform:  people told their own personal stories of living with a bleeding disorder, or sometimes shared their experiences knowing someone who has a condition.

Alain Baumann, WFH CEO

“World Hemophilia Day is a day to celebrate our dedication, and our hard work. It is also a day for us to honor and thank the healthcare professionals so devoted to our cause. They are there to support and connect our community—particularly now during the challenges of the COVID-19 pandemic.

We also set a “world record” this year. Ninety-eight landmarks around the world took part in the “Light it up Red” campaign this year. The images of those landmarks were shared on social media worldwide.

Our World Hemophilia Day microsite——is still up, so if you want to find out more about World Hemophilia Day, or read some inspiring stories, just click here.

The WFH would like to thank our 2020 World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., Biotest, CSL Behring, F. Hoffman-La Roche Ltd., GC Pharma, Grifols, Kedrion, Novo Nordisk, Octapharma, Pfizer, Precision BioLogic, Sanofi Genzyme, Sobi, Spark Therapeutics, Takeda, and uniQure.